EpiBiologics

About EpiBiologics

EpiBiologics is a biotechnology company focused on directed protein degradation using its EpiTAC platform to degrade extracellular disease-causing proteins with bispecific antibodies. The company develops tissue-selective therapies that target membrane and extracellular proteins to drive potent efficacy for cancer, autoimmune disorders, and other serious diseases. By removing disease-causing proteins and their scaffolding, EpiBiologics aims for deep and long-lasting therapeutic responses while sparing healthy tissue. Based on its science and team, the company is advancing therapeutic options for patients worldwide.